With Approval Pending, Pegcetacoplan Phase 3 Results Mixed With Approval Pending, Pegcetacoplan Phase 3 Results Mixed

With an FDA action date set, investigative complement inhibitor pegcetacoplan showed a signal for improving visual function in geographic atrophy but also a risk for conversion to wet AMD.Medscape Medical News

Source: Medscape Medical News Headlines - October 3, 2022 Category: Consumer Health News Tags: Ophthalmology News Source Type: news